Medline Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw 12% sales growth and a 13% rise in adjusted EBITDA, driven by strong demand and new customer wins. Guidance for organic sales was raised, but adjusted EBITDA was lowered due to inflation, Tracy fire costs, and operational investments. Margin pressures are being addressed with cost-saving initiatives.
-
The meeting highlighted strong 2025 performance, with $2.4 billion in new customer signings and ongoing investments in technology and product innovation. All board nominees and proposals, including executive compensation and auditor ratification, were approved.
-
Management emphasized proactive quality controls, voluntary recalls, and minimal financial impact from recent plant shutdowns. Strong Q1 growth led to raised full-year guidance, with continued investments in automation, brand penetration, and M&A. Margin improvement and long-term earnings growth are expected, supported by operational leverage and strategic capital allocation.
-
The company leverages a vertically integrated model and extensive distribution network to drive growth through prime vendor contracts and customer-focused product innovation. Despite recent FDA warning letters and inflationary pressures, guidance for 2026 remains strong, with continued investment in quality and supply chain resiliency.
-
Q1 2026 saw 11% sales growth, driven by strong Supply Chain Solutions and new customer wins, but adjusted EBITDA fell 11% due to higher costs and tariffs. Full-year organic sales guidance was raised to 8.5%-9.5%, while EBITDA guidance remains unchanged, balancing tariff relief with operational investments and inflationary headwinds.
-
Strong Q4 and FY2025 results were driven by robust new customer signings, high fill rates, and technology investments. 2026 guidance projects 8%-9% organic growth and $3.5-$3.6 billion EBITDA, with tariff headwinds expected to normalize by year-end. Expansion in labs, dental, and international markets continues.
-
Medline outlined its vertically integrated model, robust growth strategy, and focus on customer value at its first public conference appearance. Despite tariff headwinds, the company targets high single-digit revenue growth, $1B in new Prime Vendor signings annually, and margin recovery by 2027.
Fiscal Year 2025
-
Achieved double-digit sales growth and record new customer signings in 2025, with strong performance across all segments and a successful IPO strengthening the balance sheet. 2026 guidance calls for 8%-9% organic sales growth and stable EBITDA despite ongoing tariff headwinds.